Fabrice Barlési
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer(2015)9,390 cited
- → Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial(2016)4,726 cited
- → Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC(2018)3,693 cited
- → Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer(2019)2,788 cited
- → Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2016)2,632 cited
- → Sotorasib for Lung Cancers with KRAS p.G12C Mutation(2021)1,682 cited
- → KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors(2020)1,646 cited
- → Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry(2019)1,334 cited
- → Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group(2020)1,151 cited
- → Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study(2012)1,001 cited